Market revenue in 2023 | USD 70.1 million |
Market revenue in 2030 | USD 178.0 million |
Growth rate | 14.2% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.06% in 2023. Horizon Databook has segmented the China head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the largest pharmaceutical markets globally in manufacturing. A highly skilled workforce, strong healthcare infrastructure, and a strong & evolving consumer health market are some of the factors playing important roles in the development of the pharmaceuticals sector in the country.
China highly emphasizes pharmaceutical R&D activities and investments in innovative research for developing new drugs with the influence of R&D globalization. China has drawn increased interest worldwide as one of the emerging economies with the fastest-growing marketplaces.
China's contribution to the pharmaceutical industry output increased nearly sevenfold, from 2.5% in 1995 to 18.3% in 2010, with increased national policies, economic expansion, and an aging population. There is a high prevalence of head and neck cancer in China, which can drive the demand for head and neck cancer therapeutics market.
Horizon Databook provides a detailed overview of country-level data and insights on the China head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into China head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account